Hematology, Transfusion and Cell Therapy最新文献

{"title":"COMPARISON BETWEEN 18F-PSMA AND 18F-FDG RADIOTRACERS FOR PET/CT IN THE EVALUATION OF PATIENTS WITH METASTATIC MELANOMA","authors":"Thiago Soare Rocha Alves,&nbsp;Diego Mendanha,&nbsp;Ellen Lima,&nbsp;Natália Tobar,&nbsp;Juliana Souza,&nbsp;Ligia Macedo,&nbsp;Allan Oliveira Santos,&nbsp;Mariana Cunha Lopes Lima,&nbsp;Elba Etchebehere,&nbsp;Carmen Silva Passos Lima","doi":"10.1016/j.htct.2025.103786","DOIUrl":"10.1016/j.htct.2025.103786","url":null,"abstract":"<div><h3>Introduction/Justification</h3><div>PET/CT has emerged in the last two decades as a dominant imaging modality used for staging, monitoring response and surveillance of melanoma using 18F-FDG as radiotracer. Recent publications have demonstrated the possibility of use of 18F-PSMA PET/CT as an additional resource to the evaluation of melanoma, due to the expression of Prostate-Specific Membrane Antigen protein (PSMA) in these cancer cells and because anti-PSMA antibodies react with malignant melanoma neo vasculature.</div></div><div><h3>Objectives</h3><div>Would 18F-PSMA PET/CT have the potential role of a novel diagnostic imaging technique in melanoma cases?</div></div><div><h3>Materials and Methods</h3><div>Eleven participants with diagnoses of metastatic melanoma underwent 18F-FDG PET/CT and 18F-PSMA PET/CT (24-hours interval), and the lesions uptakes were evaluated with both radiotracers. The results were grouped in three categories: A - greater expression of 18F-PSMA compared to 18F-FDG; B – equivalent uptake between the radiotracers; and C - greater expression of 18F-FDG compared to 18F-PSMA.</div></div><div><h3>Results</h3><div>18,1% of participants were in category A, 54,5% in category B and 27,2% in category C. The lesions with greater 18F-PSMA uptake compared to 18F-FDG were mainly in the brain, lungs, adrenals, and scattered throughout the chest. Furthermore, one subjects presented only 18F-PSMA uptake in brain metastasis, showing the importance of this method to the clinical follow-up of these patients. Our findings align with the Chang et al.’s, who demonstrated in vitro expression of PSMA in the neovasculature of melanoma lesion and with Snow et al.’s who observed PSMA positivity in endothelial cells of capillaries within stage III/IV melanoma metastases.</div></div><div><h3>Conclusion</h3><div>Therefore, apart from the use of 18F-PSMA PET/CT in staging prostate cancer patients, this method shows a great potential in the evaluating of metastatic melanoma, still needing further and longer studies to confirm these advantages.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 ","pages":"Article 103786"},"PeriodicalIF":1.8,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143828826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MIR-4421 AS A POSSIBLE MODULATOR OF MAPK/AKT PATHWAY THROUGH ERP29 IN PHARYNGEAL CANCER","authors":"Juliana Carron ,&nbsp;Carmen Silvia Passos Lima ,&nbsp;Gustavo Jacob Lourenço","doi":"10.1016/j.htct.2025.103804","DOIUrl":"10.1016/j.htct.2025.103804","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction/Justification&lt;/h3&gt;&lt;div&gt;ERP29 gene encodes a chaperone protein essential for protein folding and secretion. Our previous study linked ERP29 inhibition to an increased risk of pharyngeal cancer (PC) and reduced patient survival, possibly due to the binding affinity between microRNA miR-4421 and ERP29 messenger RNA (mRNA). This interaction leads to ERP29 silencing, which may influence PC progression especially by decreasing necrosis and increasing cell migration. However, the precise mechanism underlying this process remains unknown, particularly its impact on well-established signaling pathways such as MAPK/Akt, which are frequently dysregulated in PC and play a critical role in tumor progression, cell survival, and metastasis.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectives&lt;/h3&gt;&lt;div&gt;This study aims to explore the role of miR-4421 and ERP29 in PC survival and progression.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Materials and Methods&lt;/h3&gt;&lt;div&gt;We first evaluated ERP29 and miR-4421 prognostic value in head and neck cancer patients assessing the Kaplan–Meier Plotter (kmplot.com/analysis/). We used PC FaDu cell line (ATCC) in two different scenarios: FaDu cisplatin (CDDP)-sensitive and FaDu CDDP-resistant (FaDu-R). ERP29 expression was silenced using a specific siRNA. We identified and validated genes modulated by ERP29 in FaDu and FaDu-R cells by TaqMan plate array and quantitative PCR (qPCR), respectively. We tested if miR-4421 inhibitor could reverse ERP29 silencing effect, with gene expression analyzed by qPCR in FaDu and FaDu-R cells. Statistical analysis was performed by t-test using SPSS 21.0 software (SPSS Incorporation, USA).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Lower ERP29 (p = 0.03) and higher miR-4421 (p &lt; 0.01) expressions were associated with poor overall survival in head and neck cancer patients. In FaDu cells, ERP29 silencing increased MAPK1 (FC: 2.4, p = 0.03), AKT1 (FC: 17.5, p &lt; 0.01), and JUN (FC: 29.0, p = 0.01) expression when compared to cells expressing ERP29. In contrast, the transfection of miR-4421 inhibitor reverted those effects, decreasing the expression of MAPK1 (FC: 0.6, p = 0.03), AKT1 (FC: 0.1, p = 0.02), and JUN (FC: 0.1, p = 0.02) compared to the negative control. In FaDu-R cells, ERP29 silencing increased SOS1 (FC: 2.2, p &lt; 0.01), MAPK1 (FC: 2.1, p &lt; 0.01), and AKT1 (FC: 2.2, p = 0.04) expression when compared to cells expressing ERP29. Conversely, miR-4421 inhibitor decreased the expression of SOS1 (FC: 0.2, p = 0.03), MAPK1 (FC: 0.4, p = 0.01), and AKT1 (FC: 0.2, p = 0.04) compared to the negative control.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;Inhibition of ERP29 expression may impact MAPK/Akt pathway, contributing to PC patients’ poor survival. However, these effects could be reversed by inhibiting the binding of miR-4421 to ERP29. Our study enhances the understanding of PC progression and CDDP resistance, and we hope that our findings will aid in the development of targeted therapy for PC patients by ensuring ERP2","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 ","pages":"Article 103804"},"PeriodicalIF":1.8,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143829766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GOLD(I)-BASED COMPLEX AUDMAP: A PROMISING ANTIPROLIFERATIVE AGENT FOR MELANOMA TREATMENT","authors":"Isabela Carvalho Diniz ,&nbsp;Fernanda Van Petten de Vasconcelos Azevedo ,&nbsp;Camilla Abbehausen ,&nbsp;Jennyfer Castro da Silva ,&nbsp;Carmen Silvia Passos Lima","doi":"10.1016/j.htct.2025.103765","DOIUrl":"10.1016/j.htct.2025.103765","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction/Justification&lt;/h3&gt;&lt;div&gt;Melanoma is the most aggressive type of skin cancer, with increasing global incidence. Platinum-based chemotherapy, particularly cisplatin, remains a standard treatment, but its effectiveness is often limited by drug resistance and severe side effects. Gold-based complexes have gained attention as potential alternatives due to their greater chemical stability, selective cytotoxicity against platinum-resistant cells, lower systemic toxicity, and immunomodulatory effects. Previous studies from our group demonstrated the antiproliferative activity of AuDMAP, a gold(I)-based complex, in the UACC-62 melanoma cell line. Building on these findings, this study investigates the antiproliferative effects, cytotoxicity, and selectivity of AuDMAP in SK-MEL-28 and A-375 melanoma cells, as well as its impact on cell migration and potential anti-metastatic properties in comparison to cisplatin.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectives&lt;/h3&gt;&lt;div&gt;To evaluate the antiproliferative activity and cell death mechanisms induced by the AuDMAP complex in SK-MEL-28 and A-375 melanoma cell lines, as well as determining its toxicity against non-tumoral HaCaT cells.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Materials and Methods&lt;/h3&gt;&lt;div&gt;Melanoma and non-tumor cells were cultured in DMEM + 10% FBS + 1% penicillin-streptomycin and treated with AuDMAP (0.78–100 µM) for 48h, with cisplatin as a control. Sulforhodamine B (SRB) and Thiazolyl Blue Tetrazolium Bromide (MTT) assays were performed to determine cell viability, antiproliferative activity, and IC50 values. The wound healing assay assessed migration, and flow cytometry will be conducted to explore cell death mechanisms and cell cycle effects.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;AuDMAP exhibited strong antiproliferative activity, inhibiting ∼80% of cell proliferation at 6.25 µM in melanoma cells - 15x more effective than cisplatin for SK-MEL-28 and 3.3x for A-375. IC50 values were 2.61 µM (SK-MEL-28), 2.50 µM (A-375), and 1.81 µM (HaCaT), yielding a low Selectivity Index (0.69–0.72). Migration assays revealed that AuDMAP significantly reduced wound closure, suggesting anti-metastatic potential. In A-375, wound closure was -8.5% with AuDMAP vs. 62.8% with cisplatin (6.25 µM), while in SK-MEL-28, closure was 4.6% vs. -13.5%, respectively. Given these promising results, further studies will focus on cell cycle analysis and death mechanisms to better understand the biological effects of AuDMAP.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;AuDMAP is a gold(I)-based complex that demonstrates potent antiproliferative and anti-migratory effects in melanoma cells, with efficacy significantly superior to cisplatin in the tested models. The inhibition of cell proliferation and migration suggests its potential as a promising anticancer agent, possibly disrupting tumor progression and metastasis. However, the low selectivity index observed indicates that its cytotoxic effects extend to non-tumor cells, raising concerns about t","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 ","pages":"Article 103765"},"PeriodicalIF":1.8,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143827747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CT-SEGMENTED BONE SUV IN MULTIPLE MYELOMA: A COMPARATIVE STUDY OF ¹⁸F-FDG AND ⁶⁸GA-PSMA PET/CT","authors":"Alexandre Mercuri Barbosa ,&nbsp;Maria Emília Seren Takahashi ,&nbsp;Stephan Pinheiro Macedo Souza ,&nbsp;Edna Marina Souza ,&nbsp;Sérgio Querino Brunetto ,&nbsp;Cármino Antonio de Souza ,&nbsp;Irene Gyongyver Heidemarie Lorand-Metze ,&nbsp;Celso Darío Ramos","doi":"10.1016/j.htct.2025.103803","DOIUrl":"10.1016/j.htct.2025.103803","url":null,"abstract":"<div><h3>Introduction/Justification</h3><div>¹⁸F-FDG PET/CT is widely used in the management of multiple myeloma (MM), a disease that often presents with extensive bone involvement. Radiolabeled prostate-specific membrane antigen (PSMA), primarily a marker for prostate cancer, is also associated with tumor neoangiogenesis, and studies have demonstrated its uptake in MM lesions. Hybrid PET/CT imaging with both FDG and PSMA tracers allows for several quantitative metrics, enabling objective comparisons beyond visual analysis.</div></div><div><h3>Objectives</h3><div>This study aims to compare ¹⁸F-FDG and ⁶⁸Ga-PSMA PET/CT quantitative metrics in the skeletal system of patients with MM.</div></div><div><h3>Materials and Methods</h3><div>The study included ¹⁸F-FDG and ⁶⁸Ga-PSMA PET/CT images acquired within a 1- to 8-day interval from 15 patients (53% male, mean age 66.7 ± 10.7 years) with symptomatic, biopsy-proven MM. CT was used to segment the entire skeleton in PET images, with the skull excluded in ¹⁸F-FDG images due to artifacts from brain uptake coregistration. SUV quantification was performed using in-house software developed in MATLAB. Descriptive statistics and individual percentage deviations between the radiotracers were used to evaluate bone mean and maximum Standardized Uptake Values (SUVmean and SUVmax). Correlation analysis between the radiotracers was conducted using Spearman's rank correlation coefficient (r) with a significance level of p &lt; 0.05.</div></div><div><h3>Results</h3><div>For bone SUVmean, values were higher for ¹⁸F-FDG compared to ⁶⁸Ga-PSMA, with an average of 0.9 ± 0.1 vs. 0.5 ± 0.1, corresponding to a -40% ± 9% difference (range: -25% to -57%). Conversely, for bone SUVmax, values were lower for ¹⁸F-FDG compared to ⁶⁸Ga-PSMA, with an average of 8 ± 3 vs. 19 ± 14, corresponding to a 154% ± 2% difference (range: -21% to 762%). A moderate correlation was found for bone SUVmean between ¹⁸F-FDG and ⁶⁸Ga-PSMA (r = 0.55, p = 0.03), while no significant correlation was observed for bone SUVmax (r = 0.17, p = 0.55).</div></div><div><h3>Conclusion</h3><div>This study reveals distinct quantitative uptake patterns between ¹⁸F-FDG and ⁶⁸Ga-PSMA PET/CT in the skeletal system of MM patients. ¹⁸F-FDG exhibited significantly higher SUVmean than ⁶⁸Ga-PSMA, likely due to physiological ¹⁸F-FDG uptake in bone marrow. A moderate correlation was observed for SUVmean between the two tracers. The higher SUVmax values for ⁶⁸Ga-PSMA, with no correlation with ¹⁸F-FDG SUVmax, may reflect the different biological targeting mechanisms of each tracer. This suggests that some regions of increased PSMA uptake (possibly indicating neoangiogenesis) may not correspond to areas of increased glycolysis, highlighting the potential complementary role of these radiotracers in MM evaluation.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 ","pages":"Article 103803"},"PeriodicalIF":1.8,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143828455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DUAL-TRACER PET/CT IMAGING IN HEPATOCELLULAR CARCINOMA: COMPARING THE PERFORMANCE OF 18F-FDG AND 18F-PSMA","authors":"Giulia Picciola Bordoni ,&nbsp;Maria Emilia Seren Takahashi ,&nbsp;Fabíola F. Zarpelão ,&nbsp;Najua A. A Silveira ,&nbsp;Victor C.C.R. Heringer ,&nbsp;Simone Kuba ,&nbsp;TobarNatália ,&nbsp;Sergio Q Brunetto ,&nbsp;Carmino A Souza ,&nbsp;José Barreto Carvalheira ,&nbsp;Celso Dario Ramos","doi":"10.1016/j.htct.2025.103802","DOIUrl":"10.1016/j.htct.2025.103802","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction/Justification&lt;/h3&gt;&lt;div&gt;Hepatocellular carcinoma (HCC) is a prevalent malignancy with rising incidence in Western countries, often diagnosed at advanced stages. Early detection and accurate assessment of tumor extent are crucial for optimal treatment planning. 18F-FDG PET/CT has limited diagnostic value in HCC. While prostate-specific membrane antigen (PSMA) is primarily a marker for prostate cancer, its association with tumor neoangiogenesis and demonstrated uptake in various malignancies, including HCC, suggests potential diagnostic applications.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectives&lt;/h3&gt;&lt;div&gt;This study compared 18F-FDG and 18F-PSMA uptake in PET/CT for evaluating hepatic lesions in HCC.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Materials and Methods&lt;/h3&gt;&lt;div&gt;Eleven patients with HCC were included, six with Barcelona Clinic Liver Cancer (BCLC) staging system stage C (advanced) and five with BCLC stage B (intermediate), with a median age of 74 years (range: 59–86). All patients underwent 18F-FDG and 18F-PSMA PET/CT scans with a one-day interval between them. 18F-FDG images were acquired at 60 and 120 minutes post-injection, while 18F-PSMA images were obtained at 90 and 150 minutes. The maximum standardized uptake value (SUVmax) was measured for all hepatic lesions, and the change between early and delayed images (ΔSUVmax) was calculated. Spearman's rank correlation coefficient (ρ) was used to assess the correlation between SUVmax values for the two radiotracers, with statistical significance set at ρ &lt; 0.05.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Nine of the 11 patients had multiple hepatic lesions. A median of 3 lesions per patient (1–15) was detected with 18F-FDG, and 2 lesions per patient (1–11) with 18F-PSMA, totaling 75 lesions. Fifty-six lesions were positive for both radiotracers, 16 were only for 18F-FDG, and 3 only for 18F-PSMA. In the BCLC-B group (n = 5), 11 lesions were detected with 18F-FDG, 15 with 18F-PSMA, and 32 with both. The median SUVmax (early images) was 6.3 (3.5–8.5) for 18F-FDG and 17.2 (15.0–25.6) for 18F-PSMA. In the BCLC-C group (n = 6), 34 lesions were detected with 18F-FDG, 14 with 18F-PSMA, and 24 with both. The median SUVmax (early images) was 8.1 (4.7–17.2) for 18F-FDG and 23.3 (17.1–50.2) for 18F-PSMA. For BCLC-B patients, the median ΔSUVmax was 17.65% (-6.35% to 28.57%) for 18F-FDG and -30.17% (-9.74% to -50.67%) for 18F-PSMA. For BCLC-C patients, the median ΔSUVmax was 0.00% (-66.67% to 10.47%) for 18F-FDG and -0.47% (-67.26% to 16.37%) for 18F-PSMA. Spearman's correlation between 18F-FDG and 18F-PSMA SUVmax was ρ = -0.5357 (ρ = 0.2357).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;The 18F-FDG and 18F-PSMA PET/CT provide complementary information for evaluating hepatic lesions in BCLC stage B and C HCC. 18F-FDG detected more lesions, particularly in advanced disease, while 18F-PSMA showed higher uptake, especially in BCLC-C patients. The lack of significant correlation between 18F-FDG and 18F-PSMA SUVmax values suggests th","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 ","pages":"Article 103802"},"PeriodicalIF":1.8,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143829765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PET/CT WITH 68GA-FAPI46 FOR THE DETECTION OF PRIMARY AND METASTATIC LESIONS IN PATIENTS WITH DIFFERENT TYPES OF CANCER. INITIAL EXPERIENCE","authors":"Lilian Yuri Itaya Yamaga,&nbsp;Gustavo Borges da Silva Teles,&nbsp;Durval Santos,&nbsp;Oren Smaletz,&nbsp;Roberto Pestana,&nbsp;Poliana Biasi,&nbsp;Mauricio Fernandes,&nbsp;Solange Amorim Nogueira,&nbsp;Marycel Figols Barboza,&nbsp;Taise Vitor,&nbsp;Jairo Wagner","doi":"10.1016/j.htct.2025.103774","DOIUrl":"10.1016/j.htct.2025.103774","url":null,"abstract":"<div><h3>Introduction/Justification</h3><div>Fibroblast activation protein (FAP), a transmembrane glycoprotein, is over expressed by cancer-associated fibroblasts in the tumor microenvironment. Radiolabeled fibroblast activation protein inhibitors (FAPI) are currently being investigated for PET imaging.</div></div><div><h3>Objectives</h3><div>To evaluate the diagnostic efficacy of PET/CT with fibroblast activation protein inhibitor (FAPI) labeled with gallium 68 (68Ga-FAPI46) for detecting primary and metastatic lesions in patients with different types of cancer.</div></div><div><h3>Materials and Methods</h3><div>Patients with different types of cancer confirmed by histopathological study were evaluated with PET/CT with 68Ga-FAPI46 for initial staging or to detect tumor recurrence. The results of PET/CT were compared to the findings of conventional imaging methods such as computed tomography and magnetic resonance imaging and with FDG PET/CT and anatomopathological studies.</div></div><div><h3>Results</h3><div>Thirty patients were evaluated, twenty two of whom were diagnosed with lung carcinoma, five with soft tissue sarcoma, one patient with each of the following tumors: gastric, breast and neuroendocrine carcinoma. High expression of FAPI was observed in most primary tumors. The diagnostic performance was high due to a favorable physiological organ distribution and low background signal leading to the detection of most metastatic lesions especially in lymph nodes, pleura, peritoneum, skeleton, liver and central nervous system. By contrast, there was false-positive 68Ga-FAPI46 uptake in inflammatory and infectious processes.</div></div><div><h3>Conclusion</h3><div>PET/CT with 68Ga-FAPI46 is a promising imaging modality for the detection of primary and metastatic lesions of many types of cancer.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 ","pages":"Article 103774"},"PeriodicalIF":1.8,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143828167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"INFLUÊNCIA DE VARIANTES GENÉTICAS EM VIAS INFLAMATÓRIAS MODULADAS PELO EGFR NO CÂNCER DE OROFARINGE","authors":"Suelen Aparecida Ribeiro de Souza ,&nbsp;Juliana Carron ,&nbsp;Maria José Ferreira Alves ,&nbsp;Miyuki Uno ,&nbsp;Leandro Luongo de Matos ,&nbsp;Luiz Paulo Kowalski ,&nbsp;Carmen Silvia Passos Lima ,&nbsp;Gustavo Jacob Lourenço","doi":"10.1016/j.htct.2025.103775","DOIUrl":"10.1016/j.htct.2025.103775","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introdução/Justificativa&lt;/h3&gt;&lt;div&gt;A superexpressão do gene EGFR ocorre na maioria dos carcinomas de células escamosas de orofaringe (CCEOF) e seus inibidores são utilizados no tratamento desses pacientes. A ativação do EGFR estimula a produção de citocinas (IL1A, IL1B e IL32) e proteínas inflamatórias (CCND1) envolvidas na origem e progressão do CCEOF. Indivíduos expostos a fatores ambientais relacionados ao CCEOF apresentam riscos distintos de desenvolver a doença, assim como pacientes com características clínico-patológicas semelhantes podem evoluir de maneiras diferentes. Variantes de nucleotídeo único (SNVs) em genes de vias inflamatórias moduladas pelo EGFR parecem influenciar essas diferenças.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objetivos&lt;/h3&gt;&lt;div&gt;Nosso objetivo foi avaliar o papel das SNVs nos genes IL1A (rs2856836, G&gt;A), IL1B (rs1143627, G&gt;A), IL32 (rs4786370, C&gt;T) e CCND1 (rs7177, A&gt;C; rs678653, C&gt;G) no risco, nas características clínico-patológicas e no prognóstico de pacientes com CCEOF.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Materiais e Métodos&lt;/h3&gt;&lt;div&gt;Foram analisados 476 pacientes com CCEOF (412 homens, 64 mulheres, média de idade: 58 anos, 413 tabagistas, 381 etilistas) diagnosticados entre janeiro de 2001 e maio de 2006: 100 no Hospital de Clínicas da USP, 66 no Hospital AC Camargo e 310 no Hospital de Clínicas da UNICAMP. Como grupo controle, investigamos 575 indivíduos saudáveis (511 homens, 64 mulheres, média de idade: 42 anos, 185 tabagistas, 290 etilistas), compostos por doadores de sangue do Hemocentro da UNICAMP. As informações clínicas e tumorais foram obtidas a partir dos prontuários e questionários específicos. As SNVs foram genotipadas por PCR em tempo real com sondas TaqMan (Life Technologies) e reagentes do kit TaqMan Universal PCR Master Mix (Applied Biosystems), seguindo as recomendações do fabricante. As diferenças entre os grupos foram avaliadas pelos testes de Fisher ou qui-quadrado (χ²). A regressão logística múltipla foi utilizada para estimar razões de chance (ORs), ajustadas por idade e tabagismo. A análise de sobrevida incluiu apenas pacientes da UNICAMP, utilizando os métodos de Kaplan-Meier e regressão de Cox. Valores de p &lt; 0,05 foram considerados significativos.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Resultados&lt;/h3&gt;&lt;div&gt;Os genótipos das SNVs apresentaram frequências similares entre pacientes e controles. Indivíduos com os distintos genótipos estiveram sob risco similares de apresentarem o CCEOF. Entretanto, algumas SNVs foram associadas a características específicas: IL1A rs2856836 (GG ou GA) foi mais frequente em tabagistas (59,3% vs. 39,0%, p = 0,003). IL1A rs2856836 (GG) foi mais comum em tumores avançados (T3 ou T4) (96,5% vs. 88,1%, p &lt; 0,001). CCND1 rs678653 (CG ou GG) foi mais prevalente em pacientes com linfonodos acometidos (68,7% vs. 53,9%, p = 0,003) e IL1B rs1143627 (GG ou GA) foi mais frequente em tumores HPV-positivos (95,9% vs. 79,1%, p = 0,01). Nenhum dos genótipos das SNVs influenciou a SLE e a SG desses pacie","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 ","pages":"Article 103775"},"PeriodicalIF":1.8,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143828168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COMPARATIVE STABILITY OF CT-BASED BONE VOLUME QUANTIFICATION USING 18F-FDG AND 68GA-PSMA PET/CT IN MULTIPLE MYELOMA","authors":"Alexandre Mercuri Barbosa ,&nbsp;Maria Emília Seren Takahashi ,&nbsp;Edna Marina Souza ,&nbsp;Sérgio Querino Brunetto ,&nbsp;Cármino Antonio de Souza ,&nbsp;Irene Gyongyver Heidemarie Lorand-Metze ,&nbsp;Celso Darío Ramos","doi":"10.1016/j.htct.2025.103795","DOIUrl":"10.1016/j.htct.2025.103795","url":null,"abstract":"<div><h3>Introduction/Justification</h3><div>Computed Tomography (CT) images obtained from hybrid nuclear medicine equipment have shown great potential for PET image segmentation. Previous studies in patients with Multiple Myeloma (MM) have demonstrated the feasibility of calculating bone volume (BV) from CT data in 18F-FDG PET/CT images. This segmentation technique allows for the extraction of variables such as mean Standardized Uptake Value (SUVmean), Percentage of Bone Involvement (PBI), and Intensity of Bone Involvement (IBI) across the entire skeleton. The aim of this study is to determine whether BV quantification based on CT Hounsfield units (HU) is stable across different radiotracers.</div></div><div><h3>Objectives</h3><div>To compare BV calculations from PET/CT scans using 18F-FDG and 68Ga-PSMA in patients with MM.</div></div><div><h3>Materials and Methods</h3><div>This study included 18F-FDG and 68Ga-PSMA PET/CT scans performed within a 1 to 8-day interval in 15 patients (53% male, mean age 66.7 ± 10.7 years) with biopsy- confirmed symptomatic MM. The study was approved by the local Ethics Committee (CAAE 91231918.0.0000.5404). BV was calculated using the Beth Israel plugin for PET image pre-segmentation, applying a threshold of HU &gt; 100. The cropped PET images were converted to binary format using FIJI, followed by the application of a morphological closing image processing tool to include areas such as bone marrow within the binary contour. For 18F-FDG PET, the skull was excluded during pre-segmentation due to overlapping artifacts caused by cerebral uptake. Descriptive statistics were used to compare FDG and PSMA BV calculations for each patient, with individual percentage deviation assessed relative to the FDG-derived BV. The correlation between BV values was evaluated using Spearman's rank correlation coefficient (rₛ), with a significance level of p &lt; 0.05.</div></div><div><h3>Results</h3><div>The average individual percentage deviation in BV between 18F-FDG PET/CT and 68Ga-PSMA PET/CT was 13 ± 3%, with a range of 7% to 20%. A strong positive correlation was observed between BV values (p = 3 × 10⁻¹⁰), with a very strong Spearman correlation coefficient (rₛ = 0.98).</div></div><div><h3>Conclusion</h3><div>Despite the exclusion of the skull in BV calculations for 18F-FDG, the results indicate a minimal decrease in BV compared to whole-skeleton BV derived from PSMA PET/CT. The very strong correlation between BV values for the two radiotracers suggests that the segmentation approach remains consistent across different PET tracers. Additionally, the proportional exclusion of the skull across patients supports the reliability of the method for BV quantification.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 ","pages":"Article 103795"},"PeriodicalIF":1.8,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143828320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SERUM METABOLOMIC ANALYSES IN RECTAL CANCER PATIENTS: AN EXPLORATORY STUDY FROM A TIME-COURSE PERSPECTIVE","authors":"Maria Carolina Santos Mendes ,&nbsp;Bruno Sérgio M Madeira ,&nbsp;Carla M Salgado ,&nbsp;Lais Rosa Viana ,&nbsp;Leisa Lopes-Aguiar ,&nbsp;Fabiana Lascala ,&nbsp;Sandra R Branbilla ,&nbsp;Renata E Contriciani ,&nbsp;Fabíola Furtuoso Zarpelão ,&nbsp;Leo Victor Kim ,&nbsp;Aglecio L Souza ,&nbsp;Sarah Monte Alegre ,&nbsp;Felipe Osorio Costa ,&nbsp;Carlos A Real Martinez ,&nbsp;Maria Cristina C Gomes-Marcondes ,&nbsp;José Barreto Campello Carvalheira","doi":"10.1016/j.htct.2025.103796","DOIUrl":"10.1016/j.htct.2025.103796","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction/Justification&lt;/h3&gt;&lt;div&gt;Patients with colorectal cancer frequently develop cachexia, leading to severe depletion of skeletal muscle. Metabolomics, through the analysis of metabolite profiles using nuclear magnetic resonance (NMR), shows promise in identifying biomarkers for diagnosis and treatment, providing crucial insights into tumours and metabolic changes, allowing for an enhanced understanding of the mechanisms related to the cancer-cachexia process.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectives&lt;/h3&gt;&lt;div&gt;In the present study, we analysed the most impacted metabolic pathways affected after a glycaemic clamp in the serum of patients with rectal cancer diagnosed with sarcopenia (S) or not (NS).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Materials and Methods&lt;/h3&gt;&lt;div&gt;In this preliminary study, serum samples collected from rectal cancer patients were prepared through filtration to remove proteins and lipids, followed by the addition of deuterium buffer for magnetic field calibration. The spectra were obtained using NMR (500 MHz), allowing precise identification and quantification of metabolites in biological samples. The obtained spectra were processed by CHENOMX software for phase adjustment, baseline correction, and spectral alignment, and then analysed for metabolic pathways using MetaboAnalyst software. Finally, metabolic profiles were correlated with clinical data from patients ((S) or (NS)) and the time course of the glycaemic clamp (initial time (T0) and final time (after 120 minutes, T1)). Institutional Review Board approval (CAAE: 91217418.2.0000.5404).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;A total of 7 patients were analysed, 3 S and 4 NS. All S were female, and NS group had 3 males and 1 female. The median age was 64 (43-66) years for S and 69 (58-74) years for the NS group. The M-value-TBW and M-value-FFM median (P25-P75) were 4,2 (3,40-5,55) and 4,4 (3,75-5,25), for the S group, and 7,20 (5,65-8,95) and 6,10 (5,63-6,63) for the NS group, respectively. Sarcopenic patients – S –, compared to NS patients, at T0, exhibited increased levels of glycerol (indicating mobilisation of body fat), glycine and threonine (suggesting lean body mass depletion), as well as methylhistidine (corresponding to skeletal muscle degradation), with maintained levels of alanine and urea. After 120 minutes (T1), S patients showed an increase in serum alanine, glycine, and urea, still with a high serum concentration of glycerol, though similar to NS patients, and a reduction in threonine and methylhistidine levels compared to NS patients. These metabolite alterations directly impacted metabolic pathway vias related to lipoic acid metabolism, glutathione metabolism, tryptophan metabolism, branched-chain amino acid degradation (leucine, isoleucine, and valine), glycolytic and gluconeogenic pathways, and pyruvate and pyrimidine metabolism in S patients compared to NS patients.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;The study reveals that S patients present a distinct metabolic pr","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 ","pages":"Article 103796"},"PeriodicalIF":1.8,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143828321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EVALUATION OF 18F-PSMA PET/CT UPTAKE IN PATIENTS WITH GASTRIC ADENOCARCINOMA: AN EXPLORATORY ANALYSIS","authors":"Renata Erbert Contriciani,&nbsp;Fabíola Furtuoso Zarpelão,&nbsp;Leo Victor Kim,&nbsp;Larissa Ariel Oliveira Carrilho,&nbsp;Sandra Regina Branbilla,&nbsp;Luiz Roberto Lopes,&nbsp;Nelson Adami Andreollo,&nbsp;Maria Emilia Seren Takahashi,&nbsp;Celso Dario Ramos,&nbsp;Maria Carolina Santos Mendes,&nbsp;Elba Cristina Sá de Camargo Etchebehere,&nbsp;José Barreto Campello Carvalheira","doi":"10.1016/j.htct.2025.103798","DOIUrl":"10.1016/j.htct.2025.103798","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction/Justification&lt;/h3&gt;&lt;div&gt;Gastric cancer is the fifth most common cancer and the third leading cause of cancer-related death worldwide. The diagnosis of gastric tumors involves a multimodal approach, including upper gastrointestinal endoscopy with biopsy, computed tomography (CT), and endoscopic ultrasound. Positron emission tomography combined with computed tomography scanners (PET/CT) is widely used in cancer diagnosis and staging as it reflects the tumor's molecular activity. However, its indication in gastric cancer is limited, being reserved for specific clinical scenarios. In this context, evaluating new imaging methods for gastric tumors becomes crucial. In recent years, PET/CT targeting PSMA (Prostate-Specific Membrane Antigen) has been explored beyond prostate cancer. PSMA expression in the endothelium of newly formed vasculature (neoangiogenesis) has already been described in other cancer types, such as colorectal, gastric, and pancreatic; however, its role in gastric cancer evaluation remains poorly understood.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectives&lt;/h3&gt;&lt;div&gt;This study aims to investigate 18F-PSMA PET/CT uptake in different clinical scenarios of patients with gastric cancer and compare it with 18F-FDG PET/CT uptake (glucose metabolism).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Materials and Methods&lt;/h3&gt;&lt;div&gt;This study was approved by the Institutional Review Board (CAAE 76237023.0.0000.5404). It was conducted in patients diagnosed with gastric adenocarcinoma treated at the Clinic Hospital of Unicamp (HC-UNICAMP) who underwent both Fludeoxyglucose F-18 (FDG) and prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) to evaluate radiotracer uptake in the primary lesion and metastases.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;A total of 24 patients with a confirmed diagnosis of gastric adenocarcinoma through upper gastrointestinal endoscopy and biopsy underwent 18F-PSMA PET/CT and 18F-FDG PET/CT. Among them, 5 had metastatic disease, and 19 had localized tumors. Among the 5 metastatic patients, 3 demonstrated PSMA uptake, of whom 2 had undergone chemotherapy before imaging, while 1 had not received chemotherapy prior to imaging. Among the 19 patients with localized tumors, 5 showed PSMA uptake, all of whom had not received neoadjuvant therapy. The remaining 14 patients showed no PSMA uptake, with 2 having undergone neoadjuvant therapy before the scan. Among these 14 patients without PSMA uptake, 6 also showed no FDG uptake, and only 1 had previously undergone neoadjuvant therapy.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;Our results demonstrated that PSMA uptake in gastric cancer is heterogeneous. It is well known that gastric cancer has high molecular, histological, and phenotypic heterogeneity, making its classification and treatment challenging. Accordingly, the findings of this descriptive analysis suggest that PET-PSMA uptake in gastric cancer may be associated with tumor biology, as well as the molecular","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 ","pages":"Article 103798"},"PeriodicalIF":1.8,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143828323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}